Skip to main content

Cancer: Medical Treatments

Volume 458: debated on Wednesday 14 March 2007

To ask the Secretary of State for Health what estimate she has made of the financial impact on the NHS of positive National Institute for Health and Clinical Excellence (NICE) appraisals for medicines for (a) lung cancer, (b) breast cancer, (c) prostate cancer, (d) bowel cancer and (e) less common cancers in each year since NICE was established. (123646)

Each technology appraisal published by the National Institute for Health and Clinical Excellence (NICE) contains an estimate of the cost to the national health service of its implementation. The table sets out NICE’s published cost impact estimates for appraisals in the relevant topic areas, up to February 2007.

Technology appraisal

Date of issue

NICE estimates of full-year costs—England (£ million)

Breast cancer

Taxanes for breast cancer

June 2000

16

Taxanes for breast cancer—review

September 2001

10

Trastuzumab for breast cancer

March 2002

17

Vinorelbine for breast cancer

December 2002

6.5

Capecitabine for locally advanced breast cancer

May 2003

-1.2

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer

August 2006

99.8

Docetaxel for early breast cancer

September 2006

8.8

Paclitaxel for early breast cancer

September 2006

10

Hormonal treatments for early breast cancer

November 2006

17.4

Gemcitabine for metastatic breast cancer

January 2007

0.08

Prostate cancer

Docetaxel for hormone refractory prostate cancer

June 2006

19.9

Bowel cancer

Laparoscopic surgery for colorectal cancer

January 2001

10

Capecitabine and tegafur with uracil for metastatic colorectal cancer

May 2003

-16

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer

April 2006

10.3

Irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer—review

August 2005

56

Laparoscopic surgery for colorectal cancer

August 2006

0.8

Bevacizumab and cetuximab for metastatic colorectal cancer

January 2007

10

Less common cancers

Taxanes for ovarian cancer

May 2000

7

Liquid Based Cytology for cervical screening

June 2000

10

Temozolomide for brain cancer

April 2001

1

Gemcitabine for pancreatic cancer

May 2001

1.9

Topetecan for advanced ovarian cancer

August 2001

7

Fludarabine for B-cell chronic lymphocytic leukaemia

September 2001

10

Rituximab for follicular non-Hodgkin’s lymphoma

March 2002

10

PLDH (Caelyx) for ovarian cancer

July 2002

3.1

Imatinib for chronic myeloid leukaemia.

October 2002

15.8

Paclitaxel for ovarian cancer

January 2003

10

Rituximab for aggressive non-Hodgkin’s lymphoma

September 2003

13.15

Liquid-based cytology for cervical screening—review

October 2003

10.1-10.3

Imatanib for chronic myeloid leukaemia

October 2003

5

Imatinib for gastro-intestinal stromal tumours (GIST)

October 2004

4.7

Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for ovarian cancer (advanced)—review

May 2005

2.25

Rituximab for follicular lymphoma

September 2006

3.4

Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

February 2007

10

1 Not considered to have significant cost implications.